Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 1, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
GlobeNewswire
·
May 1, 2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg …
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 1, 2025
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, …
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
GlobeNewswire
·
May 1, 2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic …
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 1, 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025 …
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
GlobeNewswire
·
May 1, 2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to …
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 1, 2025
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S …
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns and Canadians begin to spend more time outdoors, the Canadian Dermatology Association (CDA) launches its annual Sun Awareness Month campaign. This year’s campaign, through …
Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, 01 mai 2025 (GLOBE NEWSWIRE) -- Alors que la chaleur du soleil nous revient et que les Canadiens commencent à passer plus de temps à l’extérieur, l’Association canadienne de dermatologie (ACD) lance sa campagne annuelle du Mois de la …
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
GlobeNewswire
·
May 1, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation- …
AB Science will publish its 2024 annual financial report on May 9, 2025
GlobeNewswire
·
May 1, 2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, …
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
GlobeNewswire
·
May 1, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la publication de son rapport financier …
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
GlobeNewswire
·
May 1, 2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the development of …
Roquette Completes the Acquisition of IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition …
Roquette finalise l’acquisition d’IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la nutrition, annonce la finalisation de …
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
GlobeNewswire
·
May 1, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
GlobeNewswire
·
May 1, 2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 million, up from 8% from 2023 Q4 …
Used and new teen vehicles for every budget
GlobeNewswire
·
May 1, 2025
ARLINGTON, Va., and YONKERS, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Families with newly licensed teens have a wide range of options this year when it comes to safe vehicles for their novice driver. An updated list of suggested vehicles for teens from the …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
GlobeNewswire
·
May 1, 2025
TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today announced that the U.S. Food and Drug Administration (FDA） has cleared an investigational new drug （IND） application for OBI-902, …
浩鼎ADC OBI-902临床试验获美国FDA核准 将启动Trop-2靶向ADC 1/2期临床研究
GlobeNewswire
·
May 1, 2025
台湾, May 01, 2025 (GLOBE NEWSWIRE) -- 致力于癌症创新疗法研发的台湾浩鼎生技（4174.TWO）今（5/1）日（美国时间4/30）宣布，旗下新药OBI-902已获美国食品药物管理局（FDA）核准临床试验申请（IND），将展开一期/二期临床试验。这项试验预计招募晚期实体肿瘤患者。浩鼎视此次通过IND，为开发进程的重要里程碑，代表此一新世代Trop-2 ADC，将为未被满足医疗需求的患者提供新的治疗希望。 浩鼎执行长王慧君博士表示，即将开展的OBI-902-001 …